Apnimed Inc (APMD) Stock Analysis

Verdict: WATCH (do not buy)

AD109's Feb 28, 2027 PDUFA date offers major upside, but binary FDA approval risk and post-IPO momentum loss justify patience.

Investment score: 55/100

Analysis as of

Is Apnimed Inc stock worth reviewing? The TradeMates thesis

TradeMates assigns APMD an Investment Score of 55/100 (Watch). While the FDA acceptance of AD109's NDA with a PDUFA date of Feb 28, 2027 and a $220.8M capital raise secure runway, heavy post-IPO technical selling (-30.9% in 30 days) warrants awaiting clear technical consolidation.

7-factor investment score

Apnimed Inc opportunities and risks

What speaks for APMD

What speaks against APMD

Peers and competitors

Trailing-twelve-month ratios
TickerP/EP/SEV/EBITDAGross marginNet marginFCF yield
SGPn/a0.0xn/a0.0%0.0%-5.3%
ALMSn/a119.0xn/a88.2%-5933.5%-40.0%
ANROn/a0.0xn/a0.0%0.0%-7.8%
COLL15.5x1.0x3.2x60.0%5.9%42.6%
LXRXn/a16.4xn/a98.9%-147.4%-11.7%
Peer mediann/a1.0xn/a60.0%0.0%-7.8%

Frequently asked questions about Apnimed Inc (APMD)

Is APMD stock a good investment?

The TradeMates model rates Apnimed Inc as WATCH (do not buy) with an investment score of 55/100. TradeMates assigns APMD an Investment Score of 55/100 (Watch). While the FDA acceptance of AD109's NDA with a PDUFA date of Feb 28, 2027 and a $220.8M capital raise secure runway, heavy post-IPO technical selling (-30.9% in 30 days) warrants awaiting clear technical consolidation. This is algorithmic model output, not personal investment advice.

Is APMD stock a buy?

The TradeMates model verdict for APMD is WATCH (do not buy) with an investment score of 55/100. Treat this as a model signal to review, not a personal buy recommendation.